Aligos Therapeutics News

Aligos Therapeutics | 8-K: Current report

Jun 1 04:13

Aligos Therapeutics | 8-K: Current report

May 23 04:05

Aligos Therapeutics | 8-K: Current report

May 16 05:08

Aligos Therapeutics | 10-Q: Quarterly report

May 8 04:52

Aligos Therapeutics | 8-K: Aligos Therapeutics Reports Recent Business Progress and First Quarter 2024 Financial Results

May 8 04:14

Aligos Therapeutics | ARS: Annual Report to Security Holders

Apr 30 04:16

Aligos Therapeutics | DEFA14A: Others

Apr 30 04:10

Aligos Therapeutics | DEF 14A: Definitive information statements

Apr 30 04:07

Aligos Therapeutics | PRE 14A: Preliminary proxy statements relating to merger or acquisition

Apr 17 05:31

Aligos Therapeutics | S-8: Initial registration statement for securities to be offered to employees pursuant to employee benefit plans

Mar 13 04:55

Aligos Therapeutics | 10-K: Annual report

Mar 13 04:19

Aligos Therapeutics | 8-K: Aligos Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2023 Financial Results

Mar 13 04:11

Aligos Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Symons Julian A.

Mar 5 06:47

Aligos Therapeutics | 4: Statement of changes in beneficial ownership of securities- Calhoun Lesley Ann

Mar 5 06:47

Aligos Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer McClure Matthew W.

Mar 5 06:47

Aligos Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer BLATT LAWRENCE

Mar 5 06:46

Aligos Therapeutics | 8-K: Current report

Feb 29 11:41

Aligos Therapeutics | SC TO-I/A: Third party tender offer statement (Amendment)

Feb 29 11:40

Aligos Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Martell Bridget A

Feb 29 06:40

Aligos Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Nuechterlein Carole

Feb 29 06:40